A delegation from Airlangga University and Dr. Soetomo General Hospital visited the AroCell/IDL Biotech office in Stockholm on Tuesday, 18th of June. The Indonesian Embassy in Sweden facilitated the meeting. Airlangga University, one of the oldest medical schools in...
Last week AroCell participated in three major events across the medical and research domains. From Paris to San Diego and Copenhagen, our team presented the latest advancements and interacted with industry and scientific leaders in the field. EAU Congress 2024 In...
A recent study investigated the use of urine-based biomarkers, including UBC Rapid, to monitor high-risk non-muscle invasive bladder cancer patients. The purpose of the study was to discover new applications for these biomarkers in order to safely reduce the frequency...
We are happy to announce that two abstracts on clinical applications of AroCell TK 210 ELISA have been accepted for poster presentations at the American Association of Cancer Research 2024 (AACR 2024) held from April 5 to 10 in San Diego, USA. One of the abstracts is...
Martin Shaw, Business Development at AroCell, held a presentation on the Thymidine Kinase 1 immunoassay, highlighting its significance as a valuable translational biomarker from drug discovery through to clinical trials. You can see the presentation below....
On March 9, AroCell, Anders Hultman CEO, presented the latest developments and the future of the company at the Stockholm Corporate Finance Life Science Capital Markets Days at the IVA conference center in Stockholm. Stockholm Corporate Finance arranged the capital...
IDL Biotech has now received its first order from the company's distributor in Uganda, Medilink Lab & Surgical Ltd. The order refers to TUBEX® TF, IDL Biotech's rapid test for typhoid fever. Uganda will thus be the third country in Africa to which the company...
IDL Biotech continues to expand in Africa. IDL Biotech has signed a distributor agreement with Res Health Consult Ltd covering Ghana. The agreement covers the sale of TUBEX® TF. Since its launch in Africa, the company has focused on finding the right partners for...
IDL Biotech currently has a number of ongoing clinical studies both internationally and in Sweden, with the aim of demonstrating the clinical benefit of UBC® Rapid in bladder cancer and having the test included as a complement in the follow-up of patients with bladder...
